NMTC · NeuroOne Medical Technologies Corporation

NeuroOne’s Q2 FY2026 results reflect strong top-line growth—product revenue surged 72% YoY to $2.4M, driven by increased sales of OneRF products—while gross margin dipped modestly to 53.8% from 55.6%, suggesting stable pricing but possible mix or cost pressures. Net loss improved to $2.1M from $2.3M YoY, though the prior-year figure included a $0.4M non-operating gain on warrant liability, making the underlying operational improvement less pronounced. Operating expenses held flat at $3.4M YoY, with R&D and SG&A unchanged quarter-over-quarter, indicating disciplined spending amid pipeline advancement. The company highlighted 16 successful trigeminal neuralgia procedures with the OneRF® Trigeminal Nerve Ablation System—all patients reportedly pain-free—providing early clinical validation that may accelerate hospital adoption. Leadership additions—including David Wambeke as CBO and Christopher Volker succeeding as CFO—signal strategic focus on commercial execution and financial stewardship. ISO 13485 Stage 2 audit completion positions NeuroOne for international expansion later in 2026, contingent on certification and local regulatory approvals. Critically, cash declined to $2.8M from $6.6M over six months (Sept 2025–Mar 2026), with $2.4M in accounts receivable expected to convert in Q3—highlighting near-term liquidity sensitivity. Management emphasized catalysts including H2 FY2026 commercial launch of the sEEG-based drug delivery system for investigational use, basivertebral nerve ablation preclinical progress, and expanding epilepsy therapy collaborations—underscoring a multi-product, multi-indication growth strategy still in early commercial phase.